The Role of Estrogen-Based Hormone Therapy for Treating Prostate Cancer  – Mar 29, 2021

 

 

Summary

AnCan’s Advisory Board Member, Richard Wassersug PhD, has almost 20 years of personal experience using high dose estrogen therapy to manage his recurrent prostate cancer. Dr. Wassersug is also an expert in hormone therapy; he is the lead author of ‘Androgen Deprivation Therapy- an essential guide for prostate cancer patients ane their loved ones’. And Richard has led many studies on the psycho-social aspects of hormone therapy.

In this interactive seminar, Dr. Wassersug discusses his personal experience on estrogen based therapy. He is joined by our AnCan Brains Trust, Herb Geller and Len Sierra monitoring audience quesions, as well as PCa patient and fertiltiy endocrinologist, Dr. Mark Perloe.

Chat Log

Peter Kafka (to Everyone): 5:04 PM: I have seen reference to using Estrodile in combo with Relugolix in uterine conditions to boost hemoglobin in women, For men like myself might Estrogen with Relugolix insteade of Lupron knock down my anemia?

Mark Perloe (to Everyone): 5:05 PM: Is there a role for SERMS selective estrogen receptor modulators. in dealing with prostate cancer?

Ronald Goldberg (to Everyone): 5:09 PM: For men, which serum estradiol test do you recommend: Estradiol or Estradiol Sensative? For the estradiol sensative test, what is the “Healthy Range” for a man using estradiol to mitigate the side effects of ADT?

Ronald Goldberg (to Everyone): 5:14 PM: Is monitoring serum bone turnover markers useful to monitor bone density when on ADT?

Mark Perloe (to Everyone): 5:23 PM: Does estrogen suppress adrenal androgen production. If not, what cut-off for T suppression should be the target.

Mark Perloe (to Everyone): 5:26 PM: Isn’t much of the T behavioral effect due to aroma taste activity converting T to E.

Richard Stanton (to Everyone): 5:30 PM: What are your thoughts on whether cycling monotherapy with estradiol patches, LHRH agonists, LHRH antagonists, and ARSI’s could or might avoid, inhibit, or delay castration resistance caused by adaptive or other resistance mechanisms?

Rick Davis (to Everyone): 5:36 PM: The male breast cancer patients HATE tamoxifen.

John Ivory (to Everyone): 5:42 PM: Can you talk a little more about the mechanics of wearing the patches (is it like a bandaid? where, how often you change them, Issues of it coming off in bath/swimming/shower, how the gel is used vs. the patch)?

Herb Geller (to Everyone): 5:45 PM: Randomized Controlled Trial Eur J Endocrinol . 2018 May;178(5):565-576. doi: 10.1530/EJE-17-1072. Epub 2018 Mar 16. Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial Nicholas Russell 1 2 , Rudolf Hoermann 3 , Ada S Cheung 3 2 , Michael Ching 4 , Jeffrey D Zajac 3 2 , David J Handelsman 5 , Mathis Grossmann 3 2

John Ivory (to Everyone): 5:47 PM: Thanks, Herb. Here’s the link: https://pubmed.ncbi.nlm.nih.gov/29549104/

Patrick (to Everyone): 6:00 PM: What level does the estrogen have to be at to suppress the testosterone?

ALFRED LATIMER (to Everyone): 6:01 PM: I may be the only one here that is on estrogen. I wear three .1 patches at a time and change one patch per day. My testosterone levels and estrongen levels stay fairly consistant. I also take avodart. This combo kept my psa lees than 0.1 for almost 10years. My patches are on my upper legs Has Richard used avodart in combination?

ALFRED LATIMER (to Everyone): 6:04 PM: Could Richard repeat the discussion of not using estrogen if you have a BRAC 1 or 2 mutation.

Gary (to Everyone): 6:10 PM: When is the PATCH study likely to be done and the data published?

Herb Geller (to Everyone): 6:12 PM: Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme. Langley RE, Gilbert DC, Duong T, Clarke NW, Nankivell M, Rosen SD, Mangar S, Macnair A, Sundaram SK, Laniado ME, Dixit S, Madaan S, Manetta C, Pope A, Scrase CD, Mckay S, Muazzam IA, Collins GN, Worlding J, Williams ST, Paez E, Robinson A, McFarlane J, Deighan JV, Marshall J, Forcat S, Weiss M, Kockelbergh R, Alhasso A, Kynaston H, Parmar M. Lancet. 2021 Feb 13;397(10274):581-591. doi: 10.1016/S0140-6736(21)00100-8. PMID: 33581820

Mark Thompson Rehoboth Beach DE. (Private): 6:27 PM: Thank you very much for having this discussion.

Rick Davis (to Mark Thompson Rehoboth Beach DE.): 6:28 PM: pleasure Mark – hope it is helpful

Rich Jackson (to Everyone): 6:36 PM: Webinar: The TALK – Inherited Mutations Register here: https://bit.ly/2Oq2YkG Wednesday, March 31 2021 @ 8 pm ET, 7 pm CT, 6 pm MT, 4 pm PT, 2 pm HI

Rick Davis (to Everyone): 6:36 PM: registration for webinar https://register.gotowebinar.com/register/3736798432724445452